Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4th Edition Guidelines as A Molecular Insight towards Personalized Medicine by Hammam, Olfat et al.
  
_______________________________________________________________________________________________________________________________ 
  578                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
ID Design 2012/DOOEL Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2017 Aug 15; 5(5):578-586. 
https://doi.org/10.3889/oamjms.2017.100 
eISSN: 1857-9655 
Basic Science 
 
 
  
 
Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in 
Urothelial Lesions in the View of the WHO 4
th 
Edition Guidelines 
as a Molecular Insight towards Personalized Medicine 
 
 
 Olfat Hammam
1*
, Mona Magdy
1
, Mohamed Badawy
2
, Khalid Al Osili
2
, Amr El Kholy
2
, Tarek El LeitHy
2 
 
1
Department of Pathology, Theodor Bilharz Research Institute (TBRI), Imbaba, Giza, Egypt; 
2
Department of Urology, 
Theodor Bilharz Research Institute (TBRI), Imbaba, Giza, Egypt 
 
Citation: Hammam O, Magdy M, Badawy M, Al Osili K, 
El Kholy A, El LeitHy T. Expression of MDM2 mRNA, 
MDM2, P53 and P16 Proteins in Urothelial Lesions in the 
View of the WHO 4th Edition Guidelines as a Molecular 
Insight towards Personalized Medicine. Open Access 
Maced J Med Sci. 2017 Aug 15; 5(5):578-586. 
https://doi.org/10.3889/oamjms.2017.100 
Keywords: P53; MDM2mRNA; P16; urothelial; grade; 
bilharzia. 
*Correspondence: Professor Dr Olfat Hammam. 
Pathology Department, Theodor Bilharz Research 
Institute, El-Nile Street, Warrak El-Hadar, Imbaba P.O. 
Box 30,Giza 12411,Egypt. Mobile number:202 
01001815577. E-mail: totoali1@hotmail.com  
Received: 18-Mar-2017; Revised: 15-May-2017; 
Accepted: 19-May-2017; Online first: 05-Aug-2017 
Copyright: © 2017 Olfat Hammam, Mona Magdy, 
Mohamed Badawy, Khalid Al Osili, Amr El Kholy, Tarek El 
LeitHy. This is an open-access article distributed under 
the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 
4.0). 
Funding: This research did not receive any financial 
support. 
Competing Interests: The authors have declared that no 
competing interests exist. 
 
 
 
 
 
Abstract  
AIM: Here we imposed a multimarker molecular panel composed of P53, MDM2 protein & mRNA & P16 with the 
identification of sensitive and specific cut offs among the Egyptian urothelial carcinomas bilharzial or not 
emphasize the pathological and molecular classifications, pathways and prognosis as a privilege for adjuvant 
therapy. 
METHODS: Three hundred and ten urothelial lesions were pathologically evaluated and grouped as follows: 50 
chronic cystitis as benign, 240 urothelial carcinomas and 20 normal bladder tissue as a control. 
Immunohistochemistry for MDM Protein, P16 & p53 and In Situ Hybridization for MDM2mRNA were done. 
RESULTS: MDM2mRNA overexpression correlated with low grade low stage non invasive tumors, while P53 > 
40% & p16 < 10% cut offs correlated with high grade high stage invasive carcinomas & bilharzial tumors 
(P=0.000).  
CONCLUSION: MDM2mRNA overexpression vs. P53 > 40% & P16 < 10% constitutes a multimarker molecular 
panel with significant cut offs, proved to distinguish low grade, low stage non invasive urothelial carcinomas 
(MDM2mRNA overexpression, P53 < 40%, P16 > 10%) from high grade, high stage invasive urothelial 
carcinomas (with p53 > 40, p16 < 10% & absent MDM2mRNA overexpression). Combined P53 > 40 & p16 < 
10%, together with the histopathological features can distinguish in situ urothelial lesions from dysplastic and 
atypical lesions. 
 
 
 
 
 
 
Introduction 
 
Bladder cancer is the 7th most common 
cancer worldwide [1] and constitutes 30.3% of all 
cancers in Egypt [2]. Grading of urothelial carcinomas 
is important in noninvasive disease. Most of the 
invasive carcinomas are high grade [3].  
The 4th edition 2016 WHO guidelines 
continue to recommend the application of the grading 
classification of urothelial lesions ISUP 1997 [4] into 
two major categories as non-invasive group (whether 
papillary or flat) or invasive group with several 
advantages, among them are the definite definition of 
a high grade lesions group which has high risk of 
progression and can be candidates for adjuvant 
therapy, with elimination of diagnostic ambiguity 
particularly grade 2 lesions [3]. Also whereas low-
grade tumours are almost noninvasive (Ta), high-
grade tumours are classified based on muscle 
invasion as Non-Muscle Invasive Bladder cancer 
(NMIBC; Tis, Ta, T1) or Muscle Invasive Bladder 
cancer (MIBC; ≥ T2) [5].  
Since molecular alterations differ markedly 
between low and high grade, invasive and not 
invasive tumours [3], two distinct pathogenic 
molecular alterations documented: low-grade pathway 
which involves mutations in FGFR3, PIK3CA, and 
inactivating KDM6A mutations, whereas high-grade 
muscle-invasive tumours pathway shows TP53 and 
RB1 alterations [6].  
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Moreover, with the use of whole genome 
mRNA expression profiling, three intrinsic unique 
molecular subtypes of muscle invasive bladder 
carcinomas documented, strikingly recapitulating 
molecular subtypes of breast cancer as basal type, 
luminal type and p53-like muscle-invasive type 
tumours. The p53-like tumours are resistant to 
neoadjuvant chemotherapy. Thus, all chemoresistant 
tumours adopted a p53-like phenotype after therapy 
[7-8].  
The p53 protein is encoded by the TP53 
tumor-suppressor gene which located at 17p13.1 [9]. 
It inhibits cell-cycle progression at the G1-S transition. 
Altered p53 expression increases progressively from 
normal urothelium to in situ urothelial carcinomas (flat 
or papillary) to not muscle-invasive, to muscle-
invasive disease with metastatic lymph nodes [8, 10]. 
P53 used for urothelial carcinoma stratification [8, 11] 
however alone is not sufficient to suggest p53 
alterations and can't be used as a prognostic marker 
in urothelial carcinomas or chemotherapeutic 
response stratification [8, 12]. Therefore, a 
combination of p53 with other molecular markers 
improves risk stratification [8, 12].  
Human MDM2 gene located at 12q13–14 
[13]. It contains a p53 binding domain. MDM2 protein 
is an oncoprotein has a negative regulating effect on 
p53 [14]. MDM2 gene amplification is infrequent in 
bladder cancer despite elevated MDM2 protein levels 
[15]. MDM2 expression correlates with tumour grade 
and recurrence in superficial bladder cancer. 
Acquisition of MDM2 gene expression significantly 
associated with high tumour grade [16, 17]. 
Amplification of MDM2 may increase sensitivity to 
MDM2 antagonists [18]. In addition, the absence of 
MDM2mRNA was reported in bilharzial tumours 
indicating their aggressiveness and poor prognosis 
[18].  
P16 is an early marker for malignant 
transformation in human cancers [19, 20]. P16 is a 
TP53-related kinase that controls cell cycle 
progression. P16 gene locates at 9p21, which is a 
major site for deletions in bladder cancer. The p16 
gene abnormalities are predominant in schistosomal 
SQCC than conventional TCC. P16 and TP53 show 
mutually complementary role in the pathogenesis of 
bladder cancer [21, 22]. Loss of p16 expression is 
significantly associated with high-grade tumours and 
reduced progression-free survival [21], particularly in 
early stage bladder cancers [22].  
Moreover, mutations of genes associated with 
cell cycle control were detected in schistosomal 
bladder cancers [23]. Early deletion of P16 gene 
occurs in schistosomal TCC than schistosomal SCC 
[24]. This is due to chromosomal instability induced by 
bilharzial irritation [23-26]. Molecular subtyping of 
bladder cancer is a tool for personalized medicine [8]. 
No molecular biomarkers are widely used for clinical 
outcome prediction [21].  
Our study aimed at establishing an applicable 
multimarker molecular panel of MDM2 (mRNA & 
Protein), P16 and p53, with sensitive and specific cut 
offs, to stratify Egyptian urothelial carcinomas 
according to their molecular pathways within the 
context of WHO 2016 grade and stage classification, 
and to predict tumor progression & prognosis, 
particularly for high grade carcinomas, as a privilege 
for adjuvant therapy. 
 
 
Patients and Methods  
 
The study held on 310 urothelial lesions 
obtained from archival paraffin blocks at pathology 
department TBRI (2012-2016) and grouped as 
follows: 50 chronic cystitis as benign, 240 urothelial 
carcinomas and 20 normal bladder tissue as a control.  
 
Immunohistochemistry  
Immunohistochemistry was performed using 
antihuman monoclonal MDM2 & P53 antibodies 
(Dako, Glosturp, Denmark) at the working dilution of 
1:100. P16 monoclonal antibody (Santa Cruz 
Biotechnology, Dallas, CA, USA) was used at 1:150 
dilutions. 
 
In Situ Hybridization for MDM2mRNA 
Paraffin-embedded sections were 
deparaffinized and treated with prehybridization 
mixture. ISH was performed overnight. Human MDM2 
cDNA probe kindly provided by Bruno Voss 
(Professional Associations’ Research Institute for 
Occupational Medicine BGFA, Ruhr-University, 
Bochum, Germany) was used. The reaction signals 
were amplified by Tyramide signal amplification (TSA) 
kit (Invitrogen, Grand Island, NY). Counterstaining 
was done. Slides washed in PBS buffer and kept 
moist with glycerol.  
 
Assessment of MDM2 mRNA in Situ 
Hybridization, MDM2 protein, p16 & p53 
immunostaining 
 P16 was considered positive when at least one 
atypical cell with strong nuclear expression with 
or without cytoplasmic positivity, independently of 
the percentage of positive cells. Cases with weak 
or absent nuclear expression were considered 
negative [27]. 
 Only intense p53 and MDM2 nuclear staining 
were counted. P53 was considered positive at > 
5% cut off [28].  
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 MDM2 was considered positive at > 20% cut off 
[29, 30].  
 MDM2 mRNA was scored as follows: + normal or 
weak expression, ++ moderate expression, +++ 
overexpression. Mild (+) score was excluded. 
Moderate (++) and overexpression (+++) scores 
only were considered.  
 
Statistical analysis 
Statistical evaluation was performed with 
SPSS (version 20, IBM, Chicago, Il, USA). The 
correlation between expressions and 
clinicopathological parameters was assessed using 
Spearman's correlation test. Differences between 
proportions studied using Chi square test were 
deemed significant at the level of p < 0.05. Sensitivity, 
specificity, false positive & negative rates were 
calculated.  
 
 
Results  
 
MDM2 protein was expressed in 47.1% of 
malignant cases. All control and benign cases were 
negative. Similarly, MDM2mRNA was expressed in all 
malignant cases with negative expression in both 
benign and control cases (P<0.000) (Table 1 and 2; 
Figs. 1 & 2).  
P53 showed positive expression in 50% of 
benign cases and all malignant cases (P < 0.01). 
Surprisingly most of the non-neoplastic cases showed 
rather a variable expression up to 40%. However, 
none expressed P53 > 40% in comparison with 
urothelial carcinomas (P < 0.001). 
P16 exhibited positivity in 40% of the control 
cases (N = 4), 32% of the cystitis cases (16% of 
bilharzial cystitis & 16% of non bilharzial cystitis) and 
in all malignant cases (P < 0.001). All cystitis cases 
expressed >10% of P16. Significantly in contrast, non 
of cystitis cases showed p16 < 10% expression (p < 
0.000). 
MDM2 mRNA score was significantly 
inversely correlated with the MDM2 protein 
expression, P53 expression & score, as well as P16 
score (p < 0.001). In contrast, MDM2 protein 
expression was significantly directly correlated with 
P53 expression & score, as well as P16 score. 
Moreover, P53 expression & score were directly 
correlated with each other, with the P16 score and 
with MDM2 protein expression, however inversely 
correlated with MDM2 mRNA score (Tables 2 and 3). 
 
 
Table 1: MDM2 protein, p53 & p16 expression in relation to clinicopathological features 
 
 
MDM2 protein P53  P16 
No.  Negative  Positive  Significance  
Negative 
(<5%)  
Positive 
(>5%) 
Significance  
 
Negative 
 
<10% >10%  Significance  
Group  
Control 20 
20 
100% 
0 
0% 
P = 0. 001** 
10 
50% 
10 
50% 
P = 0. 001** 
16 
60% 
0 
0% 
4 
40% 
P=0.001** Malignant  240 
127 
52.9% 
113 
47.1% 
0 
0% 
240 
100% 
0 
0% 
167 
69.6% 
73 
30.4% 
Benign  50 
50 
100% 
0 
% 
0 
0% 
50 
100% 
42 
84% 
0 
0% 
8 
16% 
Tumor type  
TCC 154 
81 
52.6% 
73 
47.4% 
P = 0.501 
44 
28.6% 
110 
71.4% 
P = 0.001** 
0 
0% 
93 
60.4% 
61 
39.6% 
P = 0.001** 
SQCC 86 
46 
53.5% 
40 
46.5% 
48 
55.8% 
38 
44.2% 
0 
0% 
74 
86.0% 
12 
14.0% 
Invasiveness 
P = 0.001** 
 
P = 0. 001** 
 
P = 0.001** Non invasive (Ta)  46 
22 
47.8 
24 
52.2% 
33 
71.7% 
13 
28.3% 
0  
0% 
16 
34.8% 
30 
65.5% 
Invasive  194 
105 
54.1 
89 
45.9% 
59 
30.4% 
135 
69.6% 
0 
0% 
151 
77.8% 
43 
22.2% 
Stage 
T1 47 
22 
46.8% 
25 
53.2% 
P = 0.000** 
38 
80.9% 
9 
19.1% 
P = 0.001** 
0 
0% 
17 
36.2% 
30 
63.8% 
P = 0.001** T2 107 
59 
55.1% 
48 
44.9% 
6 
5.6% 
101 
94.4% 
0 
0% 
76 
71.0% 
31 
29.0% 
T3 86 
46 
53.5% 
40 
46.5% 
48 
55.8% 
38 
44.2% 
0 
0% 
74 
86.0% 
12 
14.0% 
Grade  
P = 0.01**  
  
P = 0. 001**  Low grade (G1) 28 
11 
39.3% 
17 
60.7% 
22 
78.6% 
6 
21.4% 
P = 0. 001**  
0 
0% 
10 
35.7% 
18 
64.3% 
High grade (G2-
G3)  
212 
116 
54.7% 
96 
45.3% 
70 
33% 
142 
67% 
0 
0% 
157 
74% 
55 
26% 
Bilharzia associated tumors  
P = 0.001** 
 
P = 0.0010** 
 
P = 0.094 Bilharzial  164 
99 
60.4% 
65 
39.6% 
75 
45.7% 
89 
54.% 
0 
0% 
119 
72.6% 
45 
27.4% 
Non bilharzial  76 
28 
36.8% 
48 
63.2% 
17 
22.4% 
59 
77.6% 
0 
0% 
48 
27.4% 
28 
26.8% 
**Significance differences between groups by Chi Square Test (p < 0.01); * Significance differences between groups by Chi Square Test (p < 0.05). 
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Figure 1: Immunohistochemistry expression of the MDM2 protein, 
P53 & P16. (IHC, DAB, ×200). (A) Control case showing negative 
expression of MDM2 antibody; (B) High grade (G2) invasive 
papillary urothelial carcinoma, showing P53> 40% nuclear 
expression, (in focus); (C) High grade (G3) invasive urothelial 
carcinoma showing P53 > 40% nuclear expression in the squamous 
cells (in focus); (D) High grade (G2) SQCC showing moderate 
number of nuclei positive for MDM2 antibody in the squamous cells 
(in focus); (E) Control case expressing p16 antibody (in focus); (F) 
Low grade papillary urothelial carcinoma, showing large number (> 
10%) of nuclei positive for p16 antibody, (in focus); (G) High grade 
(G3) invasive urothelial carcinoma showing few (< 10%) of nuclei 
positive for p16 antibody in the squamous cells; (H) High grade 
(G2) showing positivity (> 20%) for MDM2 antibody 
 
TCC showed significantly higher P53 
expression (71.4%) in comparison to SQCC (44.2%). 
Also, TCC significantly showed MDM2 mRNA 
overexpression in 27.9% in contrast to 11.9% of 
SQCC (P<0.01). Nevertheless, MDM2 protein showed 
no significant difference. On the other hand, 86% of 
SQCC showed significant P16<10% expression in 
contrast to only 14.5% for P16>10%. 
All urothelial carcinomas regardless their 
types expressed MDM2 mRNA. Overall, bilharzial 
association with tumours significantly inversely 
correlated with the MDM2 mRNA score (P< 0.001). In 
contrast, it showed significant direct correlation with 
MDM2 protein & P53 positivity, P53 & P16 scoring, 
tumour stage, grade & invasion (P<0.001). 
Nevertheless, 32.1% of bilharzial associated TCC 
significantly overexpressed MDM2 mRNA in contrast 
to 23.7% of the non-bilharzial associated TCC, and to 
only 11.6% of SQCC (P < 0.001). On the other hand, 
63.2% of the non bilharzial associated tumours 
showed higher MDM2 protein expression in 
comparison with 39.6% for the bilharzial associated 
tumours whether TCC or SQCC (Figs 1&2&3). 
Furthermore, 91% of bilharzial associated TCC 
significantly expressed > 40% of P53 in comparison to 
71.1% for the no bilharzial associated TCC, and to 
only 62.8% for SQCC. On the other hand, 86% of the 
SQCC (all are bilharzial) showed P16<10% in 
comparison to none bilharzial TCC (63.2%).  
Table 2: MDM2mRNA expression regarding clinicopathological 
features  
 
  MDM2 mRNA 
Significance  
No. 
Negative (- 
/normal / +1) 
Moderate 
(+2) 
Over 
expression 
(+3) 
Groups  
Control  20 
N = 10 
100% 
N = 0 
0% 
N = 0 
0% 
P = 0.001** Malignant  240 
N = 74 
30.8% 
N = 113 
47.1% 
N = 53 
22.1% 
Benign  50 
N = 50 
100% 
N = 0 
0% 
N = 0 
0% 
Tumor type  
TCC 154 
N = 42 
27.3% 
N = 69 
44.8% 
N = 43 
27.9% 
P = 0.012* 
SQCC 86 
N = 32 
37.2% 
N = 44 
51.2% 
N = 10 
11.6% 
Invasiveness 
P = 0.001** 
Non 
invasive 
(Ta)  
46 
N = 2 
4.3% 
N = 17 
37.0% 
N = 27 
58.7% 
Invasive  194 
N = 72 
37.1% 
N = 96 
49.5% 
N = 26 
13.4% 
Stage 
P = 0.001** 
T1  47 
N = 0 
0% 
N = 20 
42.6% 
N = 27 
57.4% 
T2  107 
N = 42 
39.3% 
N = 49 
45.8% 
N = 16 
15.0% 
T3 86 
N = 32 
37.2% 
N = 44 
51.2% 
N = 10 
11.6% 
Grade 
P = 0. 001** 
Low grade 
(G1) 
28 
N = 2 
7.1% 
N = 8 
28.6% 
N = 18 
64.3% 
High grade 
(G2-G3)  
126 
N = 72 
34% 
N = 105 
49.5% 
N = 35 
16.5% 
Bilharzia associated tumors 
P = 0.247 
Bilharzial  164 
N = 46 
28..0% 
N = 83 
50.6% 
N = 35 
21.3% 
Non 
bilharzial  
76 
28 
36.8% 
30 
39.5% 
18 
23.7% 
MDM2 protein expression 
Negative  187 
N = 108 
79.10% 
N = 51 
45.1% 
N = 28 
52.8% 
P = 0.001** 
Positive  113 
N = 26 
19.40% 
N = 62 
54.9% 
N = 25 
47.2% 
P53 score 
>5%-10% 50 
N = 39 
78% 
N = 4 
8% 
N = 7 
14% 
P = 0.001* 
>10%-20% 21 
N = 12 
%57.1 
N = 4 
19% 
N = 5 
23.8% 
>20%-40% 50 
N = 21 
42% 
N = 20 
40% 
N = 9 
18% 
P53>40% 179 
N = 62 
34.6% 
N = 85 
47.5% 
N = 32 
17.9% 
P16 score 
<10%  167 
57 
77% 
N = 83 
73.5% 
N = 27 
50.9% 
P = 0.001** 
>10%  85 
N = 29 
43% 
N = 30 
26.5% 
N = 26 
49.1% 
**Significance differences between groups by Chi Square Test (p < 0.01); * Significance 
differences between groups by Chi Square Test (p < 0.05). 
 
Tumor invasion significantly inversely 
correlated with the MDM2 mRNA score. Conversely, it 
directly correlated with the MDM2 protein & P53 
positivity, P53 & P16 scoring, tumor stage & grade (P 
< 0.001). About 58% of non invasive urothelial 
carcinomas showed MDM2 mRNA overexpression in 
comparison to only 13.4% of the invasive ones. 
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Figure 2. ISH staining for MDM2mRNA.  (A–D) ISH; x625. (A) 
Normal expression in a control case, showing negative expression 
of MDM2 mRNA in the urothelium. (B) Low grade papillary, 
noninvasive (G1) UC showing (+++) green signal for MDM2mRNA 
(overexpression)  in a urothelial cells (red arrow). (C) High grade 
SQCC G2-3 showing a moderate (++) green signal for MDM2 
mRNA in urothelial cells (red arrow). (D) High grade invasive UC 
associated with bilharziasis showing mild (+) green signal for MDM2 
mRNA in a urothelial cells (red arrow), bilharzial ova (yellow arrow) 
 
On the contrary, only 15% of the non invasive 
carcinomas showed P53 > 40% in comparison to 85% 
of the invasive carcinomas. Moreover, 65.2% of the 
non invasive carcinomas showed P16 > 10%, while in 
contrast 77.8% of the invasive carcinomas expressed 
< 10% of P16 (P < 0.001) (Fig. 3 and 4). 
Figure 3: Percentage of expression of MDM2 (protein & mRNA), 
P53 & P16 scores. (A) Among the studied groups; (B) Regarding 
tumour type; (C) Regarding bilharzia association in tumours 
 
Since the majority of our cases are TUR 
biopsies, T3 were excluded. Overall, tumour stage is 
significantly inversely correlated with the MDM2 
mRNA score (P < 0.001). In contrast, it directly 
correlated with MDM2 protein & P53 positivity, P53 & 
P16 scoring, tumor stage & grade (P < 0.001) (Figures 
3 and 6B). The majority of T1 carcinomas showed 
MDM2 mRNA overexpression in contrast to 15% of T2 
tumours. Conversely, T2 tumours showed highly 
significant P53 > 40% expression in 55%, in contrast 
to only 14.4%. Furthermore, 63.8% of T1 tumors 
exhibited P16 <10%, while in contrast 71% of T2 
carcinomas showed P16 < 10%.  
 
Figure 4: Percentage of expression of MDM2 (protein & mRNA), 
P53 & P16 scores. (A) Regarding tumour grade; (B) Regarding 
tumour stage; (C) Regarding invasion  
We considered G1 tumors as low grade while 
G2 & G3 tumors as high grade. Grade is significantly 
inversely correlated with the MDM2 mRNA score, 
while directly correlated with the MDM2 protein & P53 
positivity, P53 & P16 scoring, tumor stage & grade (P 
< 0.001). Majority of G1 low grade carcinomas 
(64.3%) showed MDM2 mRNA overexpression in 
contrast to the G2 & G3 high grade tumors with only 
19.1% & 20.7% respectively (P < 0.001). Conversely, 
G2 & G3 showed significant expression of P53 > 40% 
in 30.6% & 32.2% respectively, in comparison to only 
6.7 % in T1 tumors (P < 0.05). Also, 35.7% of low 
grade tumors exhibited P16 < 10% in contrast to 
94.8% in G3 high grade tumors (P < 0.001) (Figs. 3 
and 4).  
Sensitivity & specificity of the chosen cut off 
regarding the tumour grade as a milestone for the 
WHO 4th edition of urothelial lesions: From all above, 
using P53 > 40% & P16 < 10% against MDM2 mRNA 
overexpression (+++) as cut offs can stratify urothelial 
carcinomas, suggest the invasive status, stage & 
grade and predict their pathways & progression.  
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Table 3: Non-parametric correlation (Spearman's rho test) & Chi Square Test among the studied markers (N = 310) 
 
**: Correlation is significant at 0.01 level (2-tailed) by both tests; *: Correlation is significant at 0.05 level (2-tailed) by both tests; -: Inverse on parametric Spearman's rho test's 
correlation coefficient. 
 
 
  
Both P53 positivity & scoring showed near 
sensitivity & specificity values. However, P53>40% cut 
off showed better sensitivity (77.9%) but less 
specificity (88.7%) than 66.7% sensitivity & 93.8% 
specificity for positivity P53 without scoring. Moreover, 
P53>40% cut off showed an advantage of less false 
positive rate (22.1%) over 33.3% for P53 positivity 
only.  
On the other hand, MDM2 mRNA 
overexpression shows higher sensitivity (78.5%) in 
contrast to MDM2 protein positivity (45%). Moreover, 
MDM2 mRNA overexpression showed higher 
specificity (98.40 %) with lower false positive rate 
(12.5%) & lower false negative rate (1.6%) against 
81.80%, 55% & 18.20% for specificity, false positive & 
false negative rates of MDM2 protein positivity 
respectively. P16 < 10 cut off showed (78.50%) 
sensitivity, (42.40%) specificity, (26.10%) false 
positive rate and (57.60%) false negative rate.  
 
 
Discussion  
 
The challenging task in molecular pathology 
analysis is to establish the clinical relevance of 
molecular types beyond the histopathologic 
appearance [31]. Bladder cancer shouldn't be 
managed only according the clinical or pathological 
features. The molecular approach in combination with 
the clinicopathological features is mandatory. 
Nevertheless, a routine use of a well-established 
molecular approach (as in breast cancer) still not 
identified or recommended [32]. And due to tumour 
heterogeneity, no single marker can reflect the tumour 
biology. Therefore, combined biomarkers panel 
improves predictive and prognostic accuracy in order 
to get a personalized treatment approach [33].  
Here we imposed a multimarker molecular 
panel composed of P53, MDM2 protein & mRNA & 
P16 with the identification of sensitive and specific cut 
offs among the Egyptian urothelial carcinomas 
bilharzial or not. The target is to emphasize their 
pathological classification according to the WHO 4th 
edition into low vs. high grade particularly in 
ambiguous cases and to facilitate prediction of 
potential course, pathways & prognosis.  
In our study, all non-neoplastic cases showed 
neither MDM2 protein nor MDM2mRNA expression. 
Similarly, El-Abd et al., 2008 [18] showed the absence 
of MDM2mRNA in controls and benign cases. 
However, our study showed that the overexpression 
of MDM2 mRNA significantly indicated low-grade low 
stage and rather non invasive tumours with sensitivity 
(87.5 %) and high specificity (98.4 %), in contrast to 
high-grade, high stage invasive tumours. This came 
similar to Schlott et al., 2004 [34] in which 
MDM2mRNA was significantly 5-folds lower in 
advanced high grade, high stage urothelial 
carcinomas. Moreover, we showed that MDM2 mRNA 
score was inversely correlated with the MDM2 protein 
expression. Similarly, it was mentioned that MDM2 
gene amplification is infrequent in bladder cancer 
despite elevated MDM2 protein levels [34]. It is 
amplified in 10% of urothelial carcinomas [15]. 
Furthermore, we that MDM2 mRNA score 
was significantly inversely correlated with the MDM2 
protein expression, P53 expression & score, as well 
as P16 score. This may be due to that MDM2 
amplification doesn't occur with p53 mutations within 
the same tumour, indicating that carcinogenesis 
results from MDM2 amplification alone [34]. This also 
came along with Pfister et al., 2000 [35] who stated 
that tumours overexpressing MDM2 but not p53 are 
rarely of high grade. In the same context, Uchida et 
al., 2002 [36] showed that co-expression of p53 and 
MDM2 with MDM2 overexpression is associated with 
favourable prognosis in invasive carcinomas. This is 
due to loss of MDM2 inhibition and/or DNA damage 
resulting in increase of wild-type of p53 at a level not 
sufficient for immunohistochemistry detection [35]. 
However if p53 gene become mutated, tumor will 
show higher grade, worse prognosis, higher 
recurrence rate and shorter progression time & 
survival in contrast to wild type non-mutant P53 [22, 
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37].  
P53 was significantly expressed in high 
grade, high stage, invasive tumours (P<0.01) in our 
study. Furthermore, only P53>40% cut off was found 
significantly directly correlated with tumour grade, 
stage & invasiveness (P<0.001) with sensitivity 
(77.9%), specificity (88.7%), false positive rate 
(22.1%) & (11.3%) false negative rate. Coming along, 
it has been reported that p53 can help to stratify 
patients into different risk groups regarding 
progression, but not overall survival [22, 38]. Mutant 
TP53 prolongs survival of cells with established 
genetic defects, allowing them to become more 
unstable and aggressive [22].  
Moreover, surprisingly 50% of benign cases 
showed rather a variable expression of up to 40%, 
however none expressed P53>40%. Thus P53>40 cut 
off together with the cellular morphology can identify 
and distinguish the in situ urothelial lesions versus 
otherwise urothelial atypia or dysplasia. This came 
along with Cheng et al., 2014 [22] since the p53 
nuclear expression is not always indicative of TP53 
mutations, and not all TP53 mutations result in protein 
accumulation [22]. 
Immunohistochemistry relies on the 
accumulation of p53 protein due to prolonged half-life 
of cells. The half-life of wild type p53 is estimated 
between 20 and 30 min, whereas mutation there is 
decreased degradation of mutant p53 which has a 
longer half life up to 24 hours [22, 39]. A TP35 
mutation is a late event in carcinogenesis leads to 
loss of the remaining wild type allele and inactivation 
of growth control function [22, 39] resulting in an 
altered protein resistant to degradation, and shows 
nuclear accumulation, altered DNA repair, cancer 
development and progression [31, 41].  
The low p16 expression is associated with 
tumorigenesis [23, 42, 43]. Our study interestingly 
showed p16<10% expression in benign cases 
(P<0.001). Similarly, the possibility of P16 gene 
deletion in some benign and control cases was 
reported [25]. Nevertheless, the absence of p16 was 
also mentioned in benign urothelium [44]. Therefore, 
combined P16<10% and P53>40% together with 
cellular morphology can distinguish in situ urothelial 
lesions versus otherwise atypia or dysplasia. 
P16<10% cut off was significant in high grade, high 
stage, invasive tumours with (78.50%) sensitivity and 
(42.40%) specificity. Emphasis on the value of low 
p16 in the early diagnosis and prognosis of early 
stage bladder cancer as it indicates poor progression 
and recurrence free survival rates were reported 
[21,23,45]. 
P16 expression in bilharzial SQCC in 
comparison to non-bilharzial TCC was mentioned [22] 
and showed similarity to our results however with no 
significance. Additionally, we showed that bilharziasis 
significantly directly correlated with MDM2 protein & 
P53 positivity, P53 & P16 scoring, stage, grade & 
invasion and exhibited predominant P16<10% in 
tumours, while inversely correlated with MDM2 mRNA 
score, indicating aggressiveness and poor prognosis 
[18, 23].  
In conclusion, MDM2 mRNA overexpression 
vs P53>40% & P16<10% constitutes a multimarker 
molecular panel with significant cut offs, proved to 
distinguish low grade, low stage non invasive 
urothelial carcinomas (MDM2 mRNA overexpression, 
P53<40%, P16>10%) from high grade, high stage 
invasive urothelial carcinomas (with p53>40, 
p16<10% & absent MDM2mRNA overexpression). 
Also, combined P53>40 & p16<10%, together with the 
histopathological features can distinguish in situ 
urothelial lesions from dysplastic and other 
proliferative urothelial lesions. 
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